NRx Pharmaceuticals, Inc. NRXP
2.45 USD +0.30 (+13.95%)
Regular-session close
2.44 -0.01 -0.39%
Pre-market · Nov 18, 8:26 AM ET
2.09 Day range 2.47
1.62 52-week range 5.06
- YTD
- -9.59%
- 1 year
- +7.46%
News
seekingalpha.com NRx Pharmaceuticals, Inc. (NRXP) Q3 2026 Earnings Call Transcript NRx Pharmaceuticals, Inc. ( NRXP ) Q3 2026 Earnings Call November 17, 2026 8:00 AM EST Company Participants Jonathan Javitt - Co-Founder, Chairman & CEO Michael Abrams - CFO & Treasurer Conference…
marketbeat.com What NRx Pharmaceuticals (NRXP) Said on Its Q3 Earnings Call NRx Pharmaceuticals NASDAQ: NRXP reported higher third-quarter patient revenue and a narrower net loss, while outlining plans to commercialize its first approved drug and advance experimental…
globenewswire.com NRx Pharmaceuticals (Nasdaq: NRXP) Reports Third Quarter 2026 Financial Results and Provides Corporate Update FDA approved the Company's first drug, preservative-free ketamine, ahead of its GDUFA goal date; commercial launch underway with a 17-person sales forcebenzinga.com NRX Pharmaceuticals Q3 EPS $(0.05) Beats $(0.21) Estimate, Sales $1.159M Miss $1.300M Estimate NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.21) by 76.19 percent. This is a 81.48 percent increase over losses of…
zacks.com NRx Pharmaceuticals, Inc. (NRXP) Reports Q3 Loss, Misses Revenue Estimates NRx Pharmaceuticals, Inc. (NRXP) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.18 per share a year ago.
globenewswire.com NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate Update WILMINGTON, Del., Nov. 12, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a commercial biopharmaceutical company developing medicines that target…
globenewswire.com NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage WILMINGTON, Del., Nov. 11, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a commercial biopharmaceutical company developing medicines that target…
benzinga.com Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday Analysts upgraded MHK and CRWD, downgraded PFSI, cut ABOS’s target, and raised targets for NRXP, REGN and NTSK.benzinga.com Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $51 Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $50 to $51.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity…benzinga.com NRx Pharmaceuticals Receives FDA Approval Of Its Abbreviated New Drug Application For Preservative-Free Ketamine The approval comes ahead of the FDA-announced November 10, approval goal date.Preservative-Free Ketamine is an American-manufactured presentation of ketamine that contains no benzethonium chloride…
benzinga.com Why Civeo Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket Civeo shares surged 19.9% after earnings beat estimates and FY2026 sales guidance rose; other premarket movers included SLGB, HUBC and ATEC.
benzinga.com NRx Pharmaceuticals (NRXP) Stock Jumps Over 26% After Hours: What's Behind the Surge? NRx Pharmaceuticals shares jump 26.69% after hours as investors await details of a regulatory milestone for its ketamine program.benzinga.com NRx Pharmaceuticals Completes Three Process Validation Lots Of Preservative Free Ketamine Produced Under Commercial Conditions In Anticipation Of Nov. 10 Generic Drug User Fee Amendments Goal Date NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, "NRx" or "the Company"), a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central
